Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population

Table 1 Proportion of invasive lobular and infiltrating ductal histologic types according to baseline characteristics and treatment

Characteristics	Invasive lobular		Infiltrating ductal		P value
	(n = 215)		(n = 2,202)
	n	%	n	%
Age (years)
≤50	112	52.1	1,138	51.7	0.483
>50	103	47.9	1,064	48.3
Bilateral involvement
Yes	18	8.4	85	3.9	0.001
No	165	76.7	2,086	94.7
Unknown	32	14.9	31	1.4
Tumor size
T ≤ 2	103	47.9	623	28.3	<0.001
2<T ≤ 5	96	44.7	1,277	58.0
T>5	15	7.0	170	7.7
Unknown	1	0.5	132	6.0
Nodal status
0	104	48.4	1,130	51.3	<0.001
1-3	53	24.7	559	25.4
4-10	26	12.1	347	15.8
>10	29	13.5	110	5.0
Unknown	3	1.4	56	2.5
TNM
I	61	28.4	433	19.7	<0.001
II	91	42.3	1,537	69.8
III	60	27.9	215	9.8
Unknown	3	1.4	17	0.8
ER status
Negative	74	34.4	1,167	53.0	<0.001
Positive	134	62.3	1,028	46.7
Unknown	7	3.3	7	0.3
PR status
Negative	78	36.3	1,100	50.0	<0.001
Positive	130	60.5	1,053	47.8
Unknown	7	3.3	49	2.2
HR status
Negative	54	25.1	785	35.6	0.004
Positive	154	71.6	1,395	63.4
Unknown	7	3.3	22	1.0
HER2/neu status
Negative	170	79.1	1,512	68.7	0.001
Positive	31	14.4	546	24.8
Unknown	14	6.5	144	6.5
Surgery
Mastectomy	202	94.0	2,122	96.4	0.079
BCS	13	6.0	80	3.6
Chemotherapy
Undo	25	11.6	230	10.4	<0.001
MTX included	25	11.6	857	38.9
Anthracycline included	128	59.5	980	44.5
Taxane included	32	14.9	30	1.4
Others	4	1.9	10	0.5
Unknown	1	0.5	95	4.3
Radiation therapy
Undo	152	70.7	1,718	78.0	0.001
Do	60	27.9	402	18.3
Unknown	3	1.4	82	3.7
Hormonotherapy
Undo	61	28.4	1,216	55.2	<0.001
Do	150	69.8	961	43.6
Unknown	4	1.9	25	1.1

BCS, breast-conserving surgery; HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

ISSN: 1477-7819